Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

121
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
121
Cancer Survival Analysis01:21

Cancer Survival Analysis

328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Conservative management of < 3cm anterior mediastinal lesions in lung cancer screening is safe.

European radiology·2026
Same author

Symptom prevalence and impact on lung cancer risk in the SUMMIT study.

Chest·2026
Same author

More harm than good? The UK National Screening Committee's latest review of prostate cancer screening.

BJU international·2026
Same author

Correction: Ten Recommendations for Modelling Cost Effectiveness of Screening: Perspectives of an International Stakeholder Group.

PharmacoEconomics·2026
Same author

Medicaid Asset Limits And Enrollment Among Older Adults And People With Disabilities.

Health affairs (Project Hope)·2026
Same author

UK National Screening Committee position statement on evidence required for multicancer detection tests.

BMJ (Clinical research ed.)·2026
Same journal

Abstracts from Specialized Centers of Research Excellence (SCORE) on Sex Differences 2025 annual meeting.

BMC proceedings·2026
Same journal

Conference abstracts the 1st UDOM scientific conference on health: healthy lives and well-being for all: opportunities and challenges.

BMC proceedings·2026
Same journal

Entrepreneurship beyond the lab: commercializing your creative outputs.

BMC proceedings·2026
Same journal

The need to strengthen laboratory leadership, systems, and networks to enhance outbreak detection and resilience in Africa: proceedings of a regional workshop.

BMC proceedings·2026
Same journal

Abstracts from the Globesync Community Research and Sustainability 2025 (GlobeCoReS 2025).

BMC proceedings·2026
Same journal

Bauru International Craniofacial Symposium: Comprehensive Care, Policy and Advocacy Proceedings.

BMC proceedings·2026
查看所有相关文章

相关实验视频

Updated: Jun 9, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K

乳腺查工作坊中的风险分层.

Andrew Anderson1, Cristina Visintin2, Antonis Antoniou3

  • 1UK NSC secretariat, Sheffield/London, UK. Andrew.Anderson@dhsc.gov.uk.

BMC proceedings
|October 24, 2024
PubMed
概括
此摘要是机器生成的。

风险分层的乳腺癌 (BC) 查旨在根据个体风险量身定制查强度,潜在地改善与当前基于年龄的计划相比,益处和危害的平衡. 需要进一步的研究来完善模型和基础设施,以便有效实施.

关键词:
乳腺癌 乳腺癌 乳腺癌经济效益性 经济效益性流行病学 流行病学风险分层是指风险的分层.查检查 查检查 查检查

更多相关视频

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.6K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.6K

相关实验视频

Last Updated: Jun 9, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.1K
Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
06:03

Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

Published on: February 6, 2020

6.6K
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
11:34

Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers

Published on: December 5, 2017

12.6K

科学领域:

  • 在瘤学瘤学.
  • 公共卫生 公共卫生
  • 生物统计学 生物统计学

背景情况:

  • 目前英国的乳腺癌 (BC) 查针对50-71岁的女性,以减少死亡率.
  • 高风险妇女在国家计划中接受额外的查.
  • 人们对通过风险分层来个性化查越来越感兴趣.

研究的目的:

  • 评估乳腺癌风险分层查策略.
  • 通知英国国家查委员会 (UK NSC) 关于潜在的益处和危害.
  • 确定实施风险量身定制查的证据缺口.

主要方法:

  • 英国国家安全委员会研讨会的记录,讨论了风险预测和决策分析模型.
  • 专家讨论了对风险分层计划的利益危害分析和经济评估.
  • 审查目前的专家工作和初步数据.

主要成果:

  • 专家们讨论了BC查的风险预测和决策分析模型.
  • 确定进一步工作的领域包括模型比较,风险评估工具,数字基础设施,可接受性,选测试选择和减少不平等.
  • 建议逐步引入现实世界的证据评估,以实现全程序的分层.

结论:

  • 风险分层为基于年龄的乳腺癌查提供了潜在的改善.
  • 进一步的研究和仔细的规划对于成功实施至关重要.
  • 解决发现的差距对于开发有效,公平的风险量身定制的查计划至关重要.